In this study, T-3833261 and HF induced gene expression of FGF2 in a dose-dependent manner, i.e., PRS inhibitor has the ability to suppress TGF-β/Smad3 activity via upregulation of FGF2 expression. This evidence concerns the gene TGFB1 and hydrops fetalis.